
News|Articles|September 30, 2026
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
Author(s)Targeted Oncology Staff
Fact checked by: Sabrina Serani
September brought accelerated approvals in ESR1-mutant breast cancer and HER2-mutant non–small cell lung cancer, a Galleri panel vote, and a withdrawn I-DXd application.
Advertisement
Advertisement
The FDA's September 2026 oncology activity included accelerated approvals for camizestrant (Etcamah) in ESR1-mutant breast cancer and sevabertinib (Hyrnuo) in treatment-naive HER2-mutant non–small cell lung cancer (NSCLC), new approvals in cholangiocarcinoma, renal cell carcinoma (RCC), and neuroendocrine tumors, and the withdrawal of an application for ifinatamab deruxtecan (I-DXd) in small cell lung cancer.¹
Related to this article

The FDA has approved neladalkib for TKI-pretreated advanced ALK-positive NSCLC based on ALKOVE-1, requiring only 1 prior line of treatment in those who received prior alectinib.

The designation supports development of onvansertib plus FOLFIRI/bevacizumab as first-line therapy for KRAS- or NRAS-mutated metastatic colorectal cancer, based on phase 2 CRDF-004 findings.

Andrew Aguirre, MD, PhD, explained how daraxonrasib, a molecular glue RAS inhibitor, nearly doubled overall survival in previously treated pancreatic cancer.

Final PECATI results show a median PFS of 22.1 months and median OS of 40.2 months with lenvatinib plus pembrolizumab in pretreated B3 thymoma and thymic carcinoma.

The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.

During a virtual event, Richard F. Riedel, MD, and participants discussed how monitoring demands, side effects, and patient priorities shape systemic therapy selection after early recurrence of diffuse tenosynovial giant cell tumor.

The approval of pertuzumab-qcay (Pebrilzo) covers metastatic and early-stage HER2-positive breast cancer, but a patent settlement with Genentech delays its earliest US launch until the third quarter of 2028.
Advertisement
Advertisement
